Abstract |
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non-small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effects due to their strong inhibition of wild-type (WT) EGFR. Here, we report a HER2-selective covalent TKI, JBJ-08-178-01, that targets multiple HER2 activating mutations, including exon 20 insertions as well as amplification. JBJ-08-178-01 displayed strong selectivity toward HER2 mutants over WT EGFR compared with other EGFR/HER2 TKIs. Determination of the crystal structure of HER2 in complex with JBJ-08-178-01 suggests that an interaction between the inhibitor and Ser783 may be responsible for HER2 selectivity. The compound showed strong antitumoral activity in HER2-mutant or amplified cancers in vitro and in vivo. Treatment with JBJ-08-178-01 also led to a reduction in total HER2 by promoting proteasomal degradation of the receptor. Taken together, the dual activity of JBJ-08-178-01 as a selective inhibitor and destabilizer of HER2 represents a combination that may lead to better efficacy and tolerance in patients with NSCLC harboring HER2 genetic alterations or amplification. SIGNIFICANCE: This study describes unique mechanisms of action of a new mutant-selective HER2 kinase inhibitor that reduces both kinase activity and protein levels of HER2 in lung cancer.
|
Authors | Jieun Son, Jaebong Jang, Tyler S Beyett, Yoonji Eum, Heidi M Haikala, Alyssa Verano, Mika Lin, John M Hatcher, Nicholas P Kwiatkowski, Pinar Ö Eser, Michael J Poitras, Stephen Wang, Man Xu, Prafulla C Gokhale, Michael D Cameron, Michael J Eck, Nathanael S Gray, Pasi A Jänne |
Journal | Cancer research
(Cancer Res)
Vol. 82
Issue 8
Pg. 1633-1645
(04 15 2022)
ISSN: 1538-7445 [Electronic] United States |
PMID | 35149586
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2022 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Receptor, ErbB-2
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics)
- Exons
- Humans
- Lung Neoplasms
(chemically induced, drug therapy, genetics)
- Mutation
- Protein Kinase Inhibitors
(adverse effects)
- Receptor, ErbB-2
(metabolism)
|